2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory CommitteePopulation-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic
Pérez-Then E, Miric M, Qian H, Chen Y, Wang Y, Vallejo V, Quezada W, Flaquer M, Olivo J, Castillo J, García N, Calderón K, Cueto S, Veras B, Russo M, Jiménez I, Guzmán S, Garabito L, Cueto E, Colombo F, Taveras D, Torres D, Baez J, Yunen J, Koenig E, Pérez E, López O, Medina F, Wang X, Shao Y, Vermund S, Díaz G, Severino F, Acevedo A, Luciano J, Cuello J, Acevedo I, Espinál M, Martínez C, Díaz D, Espinál D, Almonte D, Rodríguez J, Rosa J, Reyes J, Fernández J, De Jesús Marte Mercado M, De Los Santos Carmona R, Liriano R, Heyliger A, Mejía A, Turbis A, Aquino C, José E, Del Rosario Y, Rosario C, Hermón J, Colón A, Flores A, Díaz C, Rodríguez D, Estrella J, Colón J, Reyes J, Gil L, Abbott M, de Mota M, Polanco N, Jiménez I, Santana R, Herrera S, Castellanos A, Germosén A, Fajardo F, Mercedes K, Méndez M, F S, Sánchez T, Payano Y, Gómez Y, Mejía Y, Sánchez D, Infante H, Grullón M, Lemos Y, Carpio P, Pineda C, Núñez M, Espiritusanto D, Álvarez G, Nina G, Cabrera K, Guerrero R, Mejía B, Nicolás K, Guante M, Lebrón M, Bidó M, Monción M, Brito E, Rosado S, de apoyo P, de Sosa A, Pimentel B, Feliciano D, de los Santos L, Morillo M, Mateo P, de la Cruz R, de los Ángeles García M, Tavárez Y, Luna R, Castillo Y, Ulloa E, Pérez E. Population-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic. Open Forum Infectious Diseases 2023, 10: ofad075. PMID: 36998630, PMCID: PMC10043129, DOI: 10.1093/ofid/ofad075.Peer-Reviewed Original ResearchSymptomatic SARS-CoV-2 infectionTest-negative case-control studyCOVID-19-related hospitalizationSARS-CoV-2 infectionCase-control studyCOVID-19 vaccineFull vaccinationAssisted ventilationPartial vaccinationLower oddsAcute respiratory syndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccination programsInactivated COVID-19 vaccineNegative case-control studySyndrome coronavirus 2 infectionPositive polymerase chain reaction testCOVID-19-related symptomsNationwide vaccination campaignPCR-positive participantsCoronavirus 2 infectionReal-world effectivenessPolymerase chain reaction testPopulation-level effectivenessSARS-CoV-2Chain reaction test
2022
Comparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosis
John BV, Doshi A, Ferreira RD, Taddei TH, Kaplan DE, Spector SA, Deng Y, Bastaich D, Dahman B. Comparison of infection‐induced and vaccine‐induced immunity against COVID‐19 in patients with cirrhosis. Hepatology 2022, 77: 186-196. PMID: 35712794, DOI: 10.1002/hep.32619.Peer-Reviewed Original ResearchConceptsPositive SARS-CoV-2 polymerase chain reactionVaccine-induced immunitySARS-CoV-2 infectionInfection-induced immunityImmunity groupsReduced oddsSARS-CoV-2 polymerase chain reactionCOVID-19Retrospective cohort studyCritical COVID-19Multivariable logistic regressionSARS-CoV-2Unvaccinated participantsUnvaccinated patientsFull vaccinationCohort studyCOVID-19 variantsCommunity prevalencePrevious infectionMRNA vaccinesPolymerase chain reactionUS veteransTreatment weightingCirrhosisPropensity scorePostvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
John BV, Deng Y, Schwartz KB, Taddei TH, Kaplan DE, Martin P, Chao H, Dahman B. Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology 2022, 76: 126-138. PMID: 35023206, PMCID: PMC9015228, DOI: 10.1002/hep.32337.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19Breakthrough COVID-19 infectionsBreakthrough COVID-19Propensity-matched cohortRetrospective cohort studyCOVID-19 patientsPfizer BNT162b2Unvaccinated participantsFull vaccinationCohort studyFirst dosePartial vaccinationMultivariable analysisSecond doseUS veteransCirrhosisReduced riskVaccine availabilityPatientsVaccinationVaccineInfectionMortalityDoseClinical and virologic factors associated with outcomes of COVID‐19 before and after vaccination among Veterans: Retrospective analysis from six New England states
Lee M, Cosentino D, Kyriakides TC, Cavallaro T, Stack G, Gupta S. Clinical and virologic factors associated with outcomes of COVID‐19 before and after vaccination among Veterans: Retrospective analysis from six New England states. Journal Of Hospital Medicine 2022, 17: 534-538. PMID: 35661577, PMCID: PMC9348310, DOI: 10.1002/jhm.12852.Peer-Reviewed Original ResearchConceptsCOVID-19Intensive care unit admissionVeterans Administration Healthcare SystemCare unit admissionNonpsychiatric hospitalizationsVirologic factorsFull vaccinationUnit admissionICU careClinical outcomesPoor outcomeMean ageRetrospective analysisD614G mutationHealthcare systemVeteransNew England statesHospitalizationOlder cohortOutcomesViral epidemiologyVaccinationDemographic factorsG mutationAgeAnalysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
Coburn SB, Humes E, Lang R, Stewart C, Hogan BC, Gebo KA, Napravnik S, Edwards JK, Browne LE, Park LS, Justice AC, Gordon KS, Horberg MA, Certa JM, Watson E, Jefferson CR, Silverberg MJ, Skarbinski J, Leyden WA, Williams CF, Althoff KN. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States. JAMA Network Open 2022, 5: e2215934. PMID: 35671054, PMCID: PMC9175076, DOI: 10.1001/jamanetworkopen.2022.15934.Peer-Reviewed Original ResearchConceptsBreakthrough infectionsFull vaccinationAdditional doseSARS-CoV-2 infection riskBreakthrough COVID-19 infectionsCOVID-19 breakthrough infectionsHIV viral load suppressionInfection riskSARS-CoV-2 infectionBreakthrough infection riskHigher CD4 countsViral load suppressionHIV viral loadAdditional vaccine dosesCOVID-19 vaccinationCOVID-19 infectionIntegrated health systemNon-Hispanic blacksCOVID-19 vaccineSARS-CoV-2Non-Hispanic whitesExpansion of RecommendationsCOVID-19 diagnosisAdvanced diseaseCD4 count
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply